A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

NCT07554456 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: BL-B01D1
DRUG: Tislelizumab
DRUG: 5-Fluorouracil
DRUG: Cisplatin
DRUG: Paclitaxel

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]